Navigation Links
Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
Date:2/13/2008

NEW YORK, Feb. 13 /PRNewswire/ -- Today, more than ever before, pharmaceutical sales and marketing executives are facing challenges from all sides. Internally, the pressure to fill pipelines, demands for more R&D results, and competition from generics demand new outcomes from pharmaceutical marketing and sales teams across the board.

Externally, new U.S.-based regulatory (e.g. post-approval monitoring), legislative, and patent issues continue to loom. Changes affecting the sales and marketing functions of the industry are inevitable as a new administration takes control of the FDA, FTC and other agencies in 2009.

International Institute for Business Information & Growth (iiBIG) presents the 2nd Annual Pharmaceutical Sales & Marketing Executive Congress, scheduled for March 31 - April 1, 2008 in Bethesda, Maryland. This year's conference will outline trends, case studies, and best-practices required to reformulate pharmaceutical marketing and sales strategies in the light of the new rules of engagement. Two new speakers to join our speaking faculty are:

-- Adriane Fugh-Berman MD, Associate Professor, Complementary and

Alternative Medicine Masters Program, Department of Physiology and

Biophysics, Georgetown University

Dr. Fugh-Berman will discuss important developments from the physician side and how physicians are responding to some irregular and wrong practices in pharma CME.

-- Lori Ryan, Executive Director, Head of Finance CVM Sales Force,

Novartis Pharmaceuticals

Ms. Ryan joins our panel on the State of the Industry - Challenges & Opportunities in 2008 and Beyond, joining distinguished faculty from Best Practices, Jazz Pharmaceuticals, and Scientific Advantage.

Dr. Fugh-Berman and Ms. Ryan joins top industry leaders in this field including Hon. Gene Green (D-TX), Member, Health Subcommittee - Energy & Commerce Committee, U. S. House of Representatives; Paul J. Savidge, VP, Global Labeling & Compliance, Bristol-Myers Squibb; Liliana A. Gil, Worldwide Director of Marketing Services & Hispanic Strategy Lead, Johnson & Johnson; and Ellen Shapiro, Director, Division of Communications, Center for Drug Evaluation and Research (CDER), FDA.

This year's agenda will review the latest developments - legislative and otherwise - from Capitol Hill to burgeoning competition to missed opportunities affecting Big Pharma's marketing, sales, and compliance efforts for market dominance.

For Conference Updates and Speaker Roster: http://www.iibig.com/P0802.


'/>"/>
SOURCE iiBIG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Healing Our Land, Inc. and The Massachusetts Black Legislative Caucus Convene Prevention Is Power Community Forum on the Impact of HIV/AIDS on Communities of Color in Massachusetts
2. MichBio Announces Formation of Biotechnology Legislative Caucus
3. Hospital-led Coalition Cautions Motorists on New Risks October 1, Lauds Legislative Leaders for Scheduling No-fault Hearings Next Week
4. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
5. AHCA: Rescinding $2.7 Billion Medicare Cuts Top Issue for Fall Legislative Agenda
6. Cipher provides CIP-TRAMADOL ER regulatory update
7. Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements
8. Mannatech Names New VP of Regulatory Affairs, Quality Assurance
9. Cardiome And Astellas Announce Regulatory Update
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... NC (PRWEB) , ... January 18, 2017 , ... The ... remain on Team V, its official endurance training and fundraising team, to compete in ... V Foundation welcomes those inspired to finish the world’s oldest annual marathon to join ...
(Date:1/18/2017)... ... January 18, 2017 , ... Park Agencies ... planning services to families and business owners in the greater Kansas City area, ... with developmental disabilities. , The Lakemary Center is a comprehensive educational resource center ...
(Date:1/18/2017)... ... 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), a ... Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. The ... thought leader interaction in, live video and interactive digital platforms. , In making ...
(Date:1/18/2017)... ... , ... Floundering on New Year’s resolutions? Need an excuse to get back ... The U.S. Apple Association agrees and recommends starting each day with apples, a ... heart disease. , The U.S. Apple Association – which represents apple growers and producers ...
(Date:1/17/2017)... California (PRWEB) , ... January 17, 2017 , ... ... have a point of difference. Eden Activewear is a stand-out company for several ... are exclusively online and only manufacture on demand, this is called 'Agile' manufacturing ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017 Research and Markets has ... 2017 - 2024" report to their offering. ... This new report revisits the ... that was issued in May of 2015. Self-healing is an area ... previous analysis we projected a market potential of $2.7 billion ($US) ...
(Date:1/17/2017)... -- Paragon Bioservices received a multiple-award, indefinite-delivery, indefinite-quantity ... a variety of National Institute of Allergy ... activities. The IDIQ mechanism will allow Paragon to ... awards up to $159 million. Paragon ... development of biopharmaceuticals, is one of four awardees ...
(Date:1/17/2017)... Management to Discuss Acquisition of ... KIT-302 Development On Track For An NDA ... Q1 2017   ... Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an innovative biopharmaceutical company, ... rd at 8:30am Eastern Time to discuss the recent acquisition of a ...
Breaking Medicine Technology: